AbbVie, Nimble
AbbVie ABBV announced that it has entered into a definitive agreement to acquire privately held biotech, Nimble Therapeutics.
AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a ...
The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target ...
US drugmaker AbbVie is to acquire Nimble Therapeutics, a USA-based Roche spinout developing oral peptide treatments in the ...
Buying Nimble Therapeutics represents AbbVie's latest deal to build out a pipeline in the wake of fading sales of its once ...
AbbVie (ABBV) and Nimble Therapeutics announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R inhibitor in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results